Allogene Therapeutics
Allogene Therapeutics raises $325M Series E at $3.9B valuation
Allogene Therapeutics: Series E Funding Round
Allogene Therapeutics has successfully raised $325M in Series E funding, reaching a valuation of $3.9B.
Company Overview
Allogeneic CAR T therapy developer
Funding Details
The Series E round was led by TPG, with participation from Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.
Company Information
- Headquarters: 210 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2017
- Employees: 700+
- Category: Biotech
Investment
Allogene Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- TPG: Verified investor in Series E
- Gilead Sciences: Verified investor in Series E
- Pfizer: Verified investor in Series E
- Frazier Healthcare Partners: Verified investor in Series E
- University of California: Verified investor in Series E
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free